Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer

Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer

Summary: Patient-derived organoids (PDOs) are widely heralded as a drug-screening platform to develop new anti-cancer therapies. Here, we use a drug-repurposing library to screen PDOs of colorectal cancer (CRC) to identify hidden vulnerabilities within therapy-induced phenotypes. Using a microscopy-...

Full description

Bibliographic Details
Main Authors: Sander Mertens, Maarten A. Huismans, Carla S. Verissimo, Bas Ponsioen, Rene Overmeer, Natalie Proost, Olaf van Tellingen, Marieke van de Ven, Harry Begthel, Sylvia F. Boj, Hans Clevers, Jeanine M.L. Roodhart, Johannes L. Bos, Hugo J.G. Snippert
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Cell Reports
Subjects:
CP: Stem cell research
CP: Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124723003352

Internet

http://www.sciencedirect.com/science/article/pii/S2211124723003352

Similar Items